Transparency reporting

GSK in Canada’s voluntary disclosure of payments to HCPs and HCOs

Woman smiling at the camera

Our commitment to transparency

GSK, like most other innovative pharmaceutical companies, engages with healthcare professionals (HCPs) who are considered experts in their field. We believe that it is appropriate to compensate healthcare professionals for their time and investment.

Globally, GSK is committed to building transparency in our operations because it enhances trust and value for patients and our healthcare system. Transparent scientific dialogue and engagement with experts is in the interests of all those working to develop new medicines and improve clinical practice and care for patients.

We are pioneers

GSK and ViiV Healthcare initiated voluntary disclosure of aggregate payments made to HCPs and HCOs in 2017. We have since expanded reporting to include payments to individual HCPs and HCP professional corporations.

 

The important relationship between industry and HCPs

The relationship between healthcare companies and HCPs is an essential part of patient care, disease understanding, as well as the research and discovery of innovative medicines in Canada.  By continuing to be transparent on these relationships, we are evolving with society’s expectations.

Group discussing in a conference room

In Scope Activities

GSK engages with HCPs and HCOs to foster scientific exchange, which benefits patients. These interactions are governed by law and regulated by Innovative Medicines Canada’s Code of Ethical Practices (PDF - 1.6 MB).

Man in button down shirt in office environment

What are payments or transfers of value (TOV)?

We are disclosing total payments made to individual HCPs. This includes payments made directly to an HCP for services, which include speaker fees, honoraria, consultations, advisory boards, as well as indirect payments, such as reimbursement of travel or accommodation associated with those services and virtual registration fees. Additionally, payments made to HCP professional corporations will be disclosed under the name of the professional corporation.
Of note, payments do not include where an HCP has withdrawn their consent to disclose this information.

Woman working in a lab

What are the collaborations for?

  • Grants to HCOs
  • Training activities and scientific professional meetings
  • R&D activities
  • Provision of services such as consulting 
Man with a rainbow lanyard in an office

What does individual disclosure mean?

We are disclosing total payments made to individual HCPs. This includes payments made directly to an HCP for services, which include speaker fees, honoraria, consultations, advisory boards, as well as indirect payments, such as reimbursement of travel or accommodation associated with those services and virtual registration fees. Additionally, payments made to HCP professional corporations will be disclosed under the name of the professional corporation.
Of note, payments do not include where an HCP has withdrawn their consent to disclose this information.